Andrei Serbanescu, MD
Neurology · Atlanta, GANPI 1528032703
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $119,648 of the $156,668 with a category attached, or 76.4%. 55 manufacturers reported payments, led by Amgen at 27.1% of the total. Reporting peaked in 2019 at $70,927 and has fallen 97.6% since, to $1,678 in 2025. Among neurology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 582 payments — averaging $269.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$42K
- EMD Serono, Inc.$33K
- Lilly USA, LLC$25K
- AbbVie$18K
- Bristol Myers Squibb$15K
- Novartis$7K
- plus $15K from 49 others
What the payments were for
- Consulting fees$19,85013%
- Speaking & faculty fees$119,64876%
- Travel & lodging$6,0804%
- Food & beverage$11,0637%
- Education$270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$156,668 in reported general payments places this provider in the 95th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 17 | $209,003 |
| Kesimpta PenOfatumumab | 15 | $127,708 |
| Nurtec OdtRimegepant Sulfate | 64 | $110,422 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 12 | $89,772 |
| CopaxoneGlatiramer Acetate | 11 | $63,122 |
| Glatiramer Acetate | 15 | $48,570 |
| GlatopaGlatiramer Acetate | 13 | $39,192 |
| QuliptaAtogepant | 36 | $38,120 |
| UbrelvyUbrogepant | 28 | $33,650 |
| Lamictal XrLamotrigine | 11 | $21,221 |
| Emgality PenGalcanezumab-Gnlm | 23 | $20,304 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 23 | $16,801 |
| Aimovig AutoinjectorErenumab-Aooe | 20 | $16,123 |
| LinzessLinaclotide | 17 | $15,917 |
| BotoxOnabotulinumtoxina | 11 | $10,540 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $115 | $209,00317 claims |
| PfizerNurtec Odt | $194 | $110,42264 claims |
| AbbVieQulipta, Ubrelvy, Linzess, Botox | $18,201 | $98,22892 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $4,590 | $63,12211 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $77 | $1,63315 claims |
| Upsher-smith Laboratories LLCTopiramate | $22 | $1,449103 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 506 neurology providers in Georgia.
Other neurology in Atlanta
- Joash LazarusAtlanta$1.1M
- Jeffrey EnglishAtlanta$749K
- Frank BerensonAtlanta$527K
- Julio FlaminiAtlanta$501K
- Douglas StuartAtlanta$493K
- Robert GilbertAtlanta$412K
- Lawrence SeidenAtlanta$272K
- Jacqueline RosenthalAtlanta$241K
- Ben ThrowerAtlanta$203K
- Jaime Hatcher MartinAtlanta$165K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.